CPM

Across TCGA pan-cancer cohorts, CPM Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CPM data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CPM Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CPM expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LUAD, UCEC, and SKCM are the cancer types where CPM Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.004	0.751	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.439	.020	22	view →
SKCM	OS	Median	All	0.998	0.774	.028	4	view →
STAD	DFS	Median	II,III,IV	1.000	0.369	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CPM–LUAD (OS)

Open the LUAD breakdown →